Research Articles Library
Literature Analysis Tools
Advanced Search
Filter by PMID, year, source, DOI and other criteria
Literature Analysis
Analyze research trends and hotspots
Batch Export
Export search results to Excel/PDF
Incidence of Inflammatory Bowel Disease in Canterbury, New Zealand, 2018-2023
Publication Year: 2025 Source: Dig Dis Sci PMID: 39746890 DOI: 10.1007/s10620-024-08811-0
BACKGROUND: New diagnoses of inflammatory bowel diseases (IBD), including Crohn's disease (CD) and ulcerative colitis (UC), can highlight health system burden and potentially give clues to disease aetiology. This population-based study aimed to measure the annual incidence of IBD over six years (2018-2023) in the Canterbury region of New Zealand. …
Trends in Mortality Due to Inflammatory Bowel Disease in the United States: A CDC WONDER Database Analysis (1999-2020)
Publication Year: 2025 Source: Dig Dis Sci PMID: 39746892 DOI: 10.1007/s10620-024-08803-0
No Abstract
Data mining and analysis of adverse events of Vedolizumab based on the FAERS database
Publication Year: 2025 Source: Sci Rep PMID: 39747183
This study aims to mine and analyze adverse events (AEs) of Vedolizumab based on the FAERS database to better understand its safety and potential risks in the real world. Data from the second quarter of 2014 to the third quarter of 2023 were collected, employing various signal mining methods such …
A stromal inflammasome Ras safeguard against Myc-driven lymphomagenesis
Publication Year: 2025 Source: Nat Immunol PMID: 39747433
The inflammasome plays multifaceted roles in cancer, but less is known about its function during premalignancy upon initial cell transformation. We report a homeostatic function of the inflammasome in suppressing malignant transformation through Ras inhibition. We identified increased hematopoietic stem cell (HSC) proliferation within the bone marrow of inflammasome-deficient mice. …
Gut microbiota and blood biomarkers in IBD-Related arthritis: insights from mendelian randomization
Publication Year: 2025 Source: Sci Rep PMID: 39747467 DOI: 10.1038/s41598-024-84116-6
With the ongoing rise in the incidence of inflammatory bowel disease (IBD), its extraintestinal manifestations have garnered significant attention. IBD-related arthritis is notable for its insidious onset and unpredictability, presenting considerable challenges for clinical diagnosis and management. Factors such as gut microbiota, plasma proteins, inflammatory proteins, and biomarkers found in …
Measurements on slope parameter mapping based on dual-energy CT enterography for improving Crohn's disease diagnosis and inflammatory activity evaluation
Publication Year: 2025 Source: Sci Rep PMID: 39747574
To explore the value of slope parameter images (SPI) derived from the dual-phase dual-energy CT enterography (DE-CTE) in the diagnosis and activity evaluation of Crohn's disease (CD). A retrospective analysis of 76 patients with CD and 53 controls who underwent dual-phase DE-CTE between January 2019 and March 2022. CD lesions …
[Application of advanced treatment in chronic inflammatory bowel diseases]
Publication Year: 2025 Source: Inn Med (Heidelb) PMID: 39747696 DOI: 10.1007/s00108-024-01833-w
BACKGROUND: The treatment options for chronic inflammatory bowel diseases (IBD) have been greatly expanded due to a better understanding of the underlying pathogenesis. A total of five classes of advanced treatment are available. OBJECTIVE: A practical overview of advanced treatment of IBD. METHODS: Narrative review. RESULTS AND DISCUSSION: Advanced treatments …
Effectiveness of tacrolimus therapy in refractory ulcerative colitis compared to infliximab with propensity score matching
Publication Year: 2025 Source: Sci Rep PMID: 39747885
There is insufficient evidence comparing the outcomes of tacrolimus-based remission induction therapy with infliximab in refractory ulcerative colitis (UC) and evidence regarding optimal strategies after tacrolimus-based remission induction therapy. We conducted a multi-institutional retrospective study of patients with UC treated with tacrolimus or infliximab between January 2010 and March 2019. …
Assessing inflammatory protein factors in inflammatory bowel Disease using multivariable mendelian randomization
Publication Year: 2025 Source: Sci Rep PMID: 39747981 DOI: 10.1038/s41598-024-84447-4
Inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Crohn's disease (CD), decreases quality of life and causes disability. The underlying processes are not fully understood. This study uses Mendelian randomization (MR) analysis to identify cytokines that may be associated with UC and CD, aiding in early diagnosis and treatment …
Frequency of Spondyloarthritis Symptoms Among US Patients With Inflammatory Bowel Disease: A Cross-Sectional Multi-Center Study
Publication Year: 2025 Source: Arthritis Care Res (Hoboken) PMID: 39748206 DOI: 10.1002/acr.25493
OBJECTIVE: Spondyloarthritis (SpA) is the most common extraintestinal manifestation of inflammatory bowel disease (IBD). The application of screening tools to detect SpA in patients with IBD may lead to earlier recognition of SpA and affect treatment decisions. METHODS: A combination of two previously described SpA screening questionnaires, the Detection of …
Need more literature?
The current database contains 98453 research articles. If you need to search for more literature or perform AI analysis, please use our knowledge acquisition module or explore external literature resources.
External Resources: Access comprehensive literature databases worldwide